Ipilimumab [477202-00-9]
Cat# T9906-10mg
Size : 10mg
Brand : TargetMol
Ipilimumab
Copy Product Info
Ipilimumab (Yervoy) is an antibody inhibitor that blocks the inhibitory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells, with immune-activating properties. Used for the treatment of unresectable or metastatic melanoma, this antibody exhibits antitumor activity.
Cas No. 477202-00-9
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.60%
Appearance:Liquid
Color:Transparent
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Ipilimumab (Yervoy) is an antibody inhibitor that blocks the inhibitory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells, with immune-activating properties. Used for the treatment of unresectable or metastatic melanoma, this antibody exhibits antitumor activity. |
| In vitro | Methods: In a co-culture system of Jurkat T cells expressing CTLA-4 and Raji B cells, anti-CD3 antibody and gradient concentrations of Ipilimumab (0–100 μg/mL) were added, and luciferase activity driven by the IL-2 promoter was detected after 4 hours of incubation. Results: Ipilimumab concentration-dependently enhanced luciferase expression (up to approximately 3-fold), and replacing with Raji cells highly expressing CD80/CD86 eliminated the early inhibitory effect produced by low concentrations of Ipilimumab. [1] |
| In vivo | Methods: In an hCTLA-4 transgenic mouse MC-38 subcutaneous xenograft tumor model, Ipilimumab was administered by intraperitoneal injection at a dose of 10 mg/kg, twice weekly for 3 consecutive weeks (control group received PBS). Results: The Ipilimumab treatment group showed complete tumor regression in 2 out of 7 mice, comparable to the efficacy of pro-Ipilimumab, confirming its antitumor activity. [2] |
| Cell Research | Objective: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. Concentrations: 0, 0.5, 5.0, and 50 μg/mL. Incubation Time: 10-14 days. Method: hPBMC were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi) or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell line or Burkitt's lymphoma cell line (Daudi). |
| Animal Research | Objective: To investigate whether Ipilimumab and PD-1 antibody enhance the ability of T cells to control the outgrowth of EBV-induced lymphomas. Formulation: PBS. Dosages: 100 μg, three times weekly |
| Reactivity | Human |
| Verified Activity | Immobilized Human CTLA-4 Protein (His) (TMPY-04348) at 10 μg/mL (100 μL/well) can bind Ipilimumab. The EC50 is 0.88 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | 1493 |
| Uniprot ID | P16410 |
| Target | CTLA-4/CD152 |
| Molecular Weight | 145.38 kDa |
| Cas No. | 477202-00-9 |
| Relative Density. | no data available |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control | Human IgG1 kappa, Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |